Jayasree K. Iyer, Executive Director

We now know which pharma companies do more against AMR Live WEF press conference News release

Antimicrobial Resistance Benchmark 2018

What pharmaceutical companies are doing to curb AMR
First independent assessment

2018 Antimicrobial Resistance Benchmark

The first detailed analysis of pharma company action against AMR, covering antimicrobial R&D, responsible manufacturing and appropriate access and stewardship.

Download AMR Benchmark

"We need a global push to fix the antibiotic market"

New white paper unpacks issues facing the security of antibiotic supply and the role for pharmaceutical companies

New white paper

Benchmark performance

GSK and Johnson & Johnson take the broadest approaches against AMR. Mylan, Cipla, Fresenius Kabi lead the generic companies. Entasis pulls ahead of the biopharmaceutical companies.

Full analysis

Company report cards

30 detailed report cards set out how each company performs against the Benchmark metrics, including portfolio and pipeline analyses and opportunities for further action.

View Report Cards
News & events
31 May 2018
Access to Medicine Foundation makes case for fixing the antibiotic market

Today, the Access to Medicine Foundation warns that antibiotic supply chains are on the brink of collapse, putting basic healthcare at risk, in a new white paper titled “Shortages, stockouts and scarcity: the

research SCOPES

Company scope30 companies


Disease scopeInfectious diseases/pathogens


Product scopeAntimicrobial medicines and vaccines


Geographic scopeGlobal


A. Research & Development

This area assesses:

  • Antimicrobial pipelines of medicines and vaccines
  • R&D for pathogens defined as AMR priorities by WHO
  • Investments in R&D
  • Plans for ensuring successful candidates are available and used wisely
Read more

B. Manufacturing & Production

This area assesses:

  • Strategies for reducing antibiotic discharge in factory wastewaters
  • Whether strategies are applied to third-party suppliers
  • Companies’ commitment to Good Manufacturing Practices
  • Transparency around audits and environmental risk management
Read more

C. Appropriate Access & Stewardship

This area assesses:

  • Whether companies educate healthcare professionals on antibiotic stewardship
  • Pricing and registration of antibiotics
  • Practices related to appropriate antibiotic marketing and promotion
  • How companies support efforts to track resistance (surveillance)
Read more
Expert views on the Benchmark

The Antimicrobial Resistance Benchmark research programme is made possible
with financial support from: